Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.99 HKD | +4.21% | -3.88% | -50.50% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.50% | 82.17M | - | ||
+9.42% | 114B | B+ | ||
+11.84% | 104B | B+ | ||
-14.15% | 22.41B | B+ | ||
-1.05% | 22.28B | B | ||
-5.29% | 19.07B | A- | ||
-38.29% | 18B | A- | ||
-4.16% | 17.89B | B | ||
+7.99% | 14.28B | C+ | ||
+36.24% | 12.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6996 Stock
- Ratings Antengene Corporation Limited